The influence of lactate Ringer solution versus hydroxyethyl starch on coagulation and fibrinolytic system in patients with septic shock

OBJECTIVE: To investigate the influence of lactate Ringer solution (RL) versus hydroxyethyl starch 130/0.4 (HES130/0.4) solution on coagulation and fibrinolytic system in the patients with septic shock

Bibliographische Detailangaben
Veröffentlicht in:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue. - 1998. - 24(2012), 1 vom: 15. Jan., Seite 38-41
1. Verfasser: Lv, Jie (VerfasserIn)
Weitere Verfasser: Zhao, Hui-ying, Liu, Fang, An, You-zhong
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2012
Zugriff auf das übergeordnete Werk:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
Schlagworte:Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't HES 130-0.4 Hydroxyethyl Starch Derivatives Isotonic Solutions Plasminogen Activator Inhibitor 1 Ringer's Lactate Tissue Plasminogen Activator EC 3.4.21.68
LEADER 01000caa a22002652 4500
001 NLM214590976
003 DE-627
005 20250213135416.0
007 tu
008 231224s2012 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0715.xml 
035 |a (DE-627)NLM214590976 
035 |a (NLM)22248750 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Lv, Jie  |e verfasserin  |4 aut 
245 1 4 |a The influence of lactate Ringer solution versus hydroxyethyl starch on coagulation and fibrinolytic system in patients with septic shock 
264 1 |c 2012 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 30.07.2012 
500 |a Date Revised 11.03.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To investigate the influence of lactate Ringer solution (RL) versus hydroxyethyl starch 130/0.4 (HES130/0.4) solution on coagulation and fibrinolytic system in the patients with septic shock 
520 |a METHODS: Forty-two consecutive patients with septic shock diagnosed between September 2009 and June 2011 were randomized to two study groups: RL resuscitation group (RL group) with 20 patients, and HES130/0.4 resuscitation group (HES group) with 22 patients. In all of them peripheral blood was collected at four points of time: before resuscitation, 6, 12, 24 hours after resuscitation, and then prothrombin time (PT), activated partial thromboplastin time (APTT) and levels of plasma tissue plasminogen activator (t-PA), and plasminogen activator inhibitor (PAI) were determined. Meanwhile, the patients' outcome and the length of intensive care unit stay (ICU-LOS) were recorded 
520 |a RESULTS: ICU-LOS (days) in HES group was significantly shorter than the RL group (12.5 ± 8.8 vs. 17.1 ± 16.6, P < 0.01). Meanwhile, the volume of fluid (L: 2.77 ± 0.59) as well as vasoactive drugs [μg×kg(-1)×min(-1): 0.56 ± 0.15] used in the HES group were significantly lower than RL group (3.46 ± 0.73, 0.81 ± 0.41, both P < 0.01). In RL group, 12 patients died and 8 patients survived, while in HES group, 7 patients died and 15 patients survived, showing no difference between two groups. PT, APTT and the levels of t-PA showed no significant differences between two groups at different time points, but the levels of plasma PAI (μg/L) of the HES group decreased gradually, and was significantly lower than that before resuscitation and RL group at 24 hours after resuscitation (41.76 ± 25.95 vs. 89.11 ± 14.27, 55.08 ± 35.43, both P < 0.05) 
520 |a CONCLUSIONS: Both RL and HES130/0.4 fluid resuscitation did not affect the outcome of the patients with septic shock, but the resuscitation efficiency of HES130/0.4 is much better than RL. Both type of fluids did not show the effect on coagulability of the septic patients, but colloid fluid resuscitation may protect the vascular endothelial cell, reduce the inhibition of fibrinolytic system, and alleviate hypercoagulability state of patients in early stage 
650 4 |a Comparative Study 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a HES 130-0.4  |2 NLM 
650 7 |a Hydroxyethyl Starch Derivatives  |2 NLM 
650 7 |a Isotonic Solutions  |2 NLM 
650 7 |a Plasminogen Activator Inhibitor 1  |2 NLM 
650 7 |a Ringer's Lactate  |2 NLM 
650 7 |a Tissue Plasminogen Activator  |2 NLM 
650 7 |a EC 3.4.21.68  |2 NLM 
700 1 |a Zhao, Hui-ying  |e verfasserin  |4 aut 
700 1 |a Liu, Fang  |e verfasserin  |4 aut 
700 1 |a An, You-zhong  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue  |d 1998  |g 24(2012), 1 vom: 15. Jan., Seite 38-41  |w (DE-627)NLM098227793  |x 1003-0603  |7 nnns 
773 1 8 |g volume:24  |g year:2012  |g number:1  |g day:15  |g month:01  |g pages:38-41 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 24  |j 2012  |e 1  |b 15  |c 01  |h 38-41